Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections

Posaconazole is used for prophylaxis for invasive fungal infections (IFIs) among patients with hematologic malignancies. We compared the incidence of breakthrough IFIs and early discontinuation between patients receiving delayed-release tablet and oral suspension formulations of posaconazole. This w...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Antimicrob Agents Chemother
Autori principali: Furuno, Jon P., Tallman, Gregory B., Noble, Brie N., Bubalo, Joseph S., Forrest, Graeme N., Lewis, James S., Bienvenida, Ana F., Holmes, Courtney A., Weber, Bo R., McGregor, Jessina C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2018
Soggetti:
Clinical Therapeutics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6153813/
https://ncbi.nlm.nih.gov/pubmed/30012757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00893-18
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi